Aetna modified CPB 0375 governing photodynamic therapy coverage, effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0375, which controls photodynamic therapy (PDT) coverage for commercial medical plans. The CPB 0375 Aetna system covers 13 CPT codes and four HCPCS codes across dermatologic, endoscopic, and oncologic PDT applications. If your team bills CPT 96567, 96573, 96570, 96571, J7308, J7345, or J9600 for Aetna commercial members, this coverage policy update applies to you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna (Commercial Plans) |
| Policy | Photodynamic Therapy — CPB 0375 |
| Policy Code | CPB 0375 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, Gastroenterology, Pulmonology, Oncology, Otolaryngology |
| Key Action | Audit charge capture and ICD-10 linkage for all PDT claims before submitting against the September 26, 2025 effective date |
Aetna Photodynamic Therapy Coverage Criteria and Medical Necessity Requirements 2025
The Aetna photodynamic therapy coverage policy divides PDT into two broad delivery methods: external application to the skin and endoscopic application to internal structures. Each method has its own covered CPT codes and its own medical necessity rules.
For external, skin-directed PDT, Aetna covers CPT 96567 and CPT 96573 when medical necessity criteria are met. CPT 96567 applies to destroying pre-malignant or malignant lesions using external light. CPT 96573 targets premalignant skin lesions specifically, including actinic keratoses.
The photosensitizing drug matters as much as the procedure code. Aetna covers HCPCS J7308 (aminolevulinic acid HCL, 20%, 354 mg) and J7345 (aminolevulinic acid HCL, 10% gel, 10 mg) when used in covered indications. Porfimer sodium (J9600, 75 mg) is covered for covered endoscopic and oncologic indications. Your ICD-10 coding must support the specific indication — Aetna's code list for this CPB runs to 527 diagnosis codes, so a mismatch between your procedure code and diagnosis will trigger a claim denial.
For endoscopic PDT, Aetna covers CPT 96570 (first 30 minutes) and CPT 96571 (each additional 15 minutes) under specific conditions. Both codes appear twice in the policy — once in the covered group and once in the not-covered group. That distinction is indication-driven. The same CPT code can be covered or denied depending entirely on what ICD-10 code you attach.
This policy covers commercial plans only. For Medicare PDT billing, Aetna directs you to Medicare Part B criteria, which are separate. Don't apply commercial CPB 0375 criteria to Medicare Advantage claims without confirming the plan-specific rules.
Prior authorization requirements for photodynamic therapy billing under Aetna commercial plans are not explicitly enumerated in the CPB text, but high-cost oncologic PDT — particularly porfimer sodium (J9600) at $750+ per unit — warrants prior auth verification before treatment. Check the specific plan's benefits configuration. A single J9600 denial without prior auth is an expensive lesson.
Aetna Photodynamic Therapy Exclusions and Non-Covered Indications
The biggest trap in this policy is the dual-listed endoscopic codes. CPT 96570 and CPT 96571 appear in both the covered and not-covered groups. Aetna covers these codes for specific, medically necessary indications — but they are explicitly not covered when billed for indications listed elsewhere in the CPB.
The same logic applies to the related endoscopic procedure codes. CPT 31641 (bronchoscopy with tumor destruction), CPT 43228, 43229 (esophagoscopy with ablation), CPT 43270 (EGD with ablation), CPT 43272, and CPT 43278 (ERCP with ablation) are all listed as "other CPT codes related to the CPB." These aren't covered or excluded outright — they're contextually relevant, meaning Aetna may reference them when reviewing claims that include PDT codes.
HCPCS J7309 — methyl aminolevulinate (MAL), 16.8% topical — is explicitly not covered. The policy flags it as a discontinued product. If you have any charge capture templates still referencing J7309, remove it now. Any claim billed with J7309 will deny.
CPT 96574 (debridement of premalignant hyperkeratotic lesions followed by PDT) is also in the not-covered group. This code is sometimes billed as a precursor service before PDT application. Aetna's position is clear — it doesn't cover it for the indications listed in this CPB.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Premalignant & malignant skin lesions (external PDT) | Covered when criteria met | CPT 96567, 96573; J7308, J7345 | Medical necessity documentation required |
| Endoscopic PDT for covered oncologic/GI indications | Covered when criteria met | CPT 96570, 96571; J9600 | Indication-specific — see not-covered exclusions |
| Obstructing esophageal malignancy (C15.3–C15.9) | Covered when criteria met | CPT 96570, 96571; J9600; CPT 43228, 43229 | Verify plan-level prior auth |
| Endobronchial non-small cell lung cancer (C34.x) | Covered when criteria met | CPT 96570, 96571; J9600; CPT 31641 | Microinvasive or obstructing only |
| Cholangiocarcinoma / bile duct malignancy (C22.x) | Covered when criteria met | CPT 96570, 96571; J9600; CPT 43272, 43278 | ERCP-delivered PDT |
| Pancreatic malignancy (C25.x) | Covered when criteria met | CPT 96570, 96571; J9600 | Verify specific plan criteria |
| Endoscopic PDT for indications listed as excluded | Not Covered | CPT 96570, 96571 | Same codes — indication determines coverage |
| Debridement prior to PDT | Not Covered | CPT 96574 | Explicitly excluded in CPB 0375 |
| MAL topical (methyl aminolevulinate) | Not Covered | HCPCS J7309 | Product discontinued — do not bill |
| Dermatologic non-malignant/viral conditions (warts, mycosis, herpes) | Not Covered | A63.0, B00.1, B07.0, B07.8, B35.x, B36.0 | These ICD-10 codes appear in the CPB — PDT not covered for these indications |
Aetna Photodynamic Therapy Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit your charge capture templates before September 26, 2025. Remove HCPCS J7309 from any active templates. It's discontinued and will deny. Add J7308 and J7345 as the active aminolevulinic acid codes. |
| 2 | Review ICD-10 linkage for every PDT claim. With 527 diagnosis codes in this CPB, the line between covered and not-covered is entirely diagnosis-driven. Your coders need to know which ICD-10 codes map to covered indications before claims go out. |
| 3 | Flag CPT 96570 and 96571 claims for manual review. These codes are covered or not covered based on indication. Build a billing guideline into your workflow: any claim with 96570 or 96571 needs explicit confirmation that the attached ICD-10 falls in the covered group, not the excluded group. |
| 4 | Verify prior authorization for porfimer sodium (J9600) at the plan level. This is a high-cost drug. Reimbursement denial after treatment is delivered is a serious financial exposure. Confirm prior auth requirements with each Aetna commercial plan before administering J9600. |
| 5 | Do not bill CPT 96574 for Aetna commercial claims. Aetna's coverage policy explicitly excludes it for indications in this CPB. If your dermatologists perform curettage before PDT application, document it carefully but understand that separate reimbursement for 96574 is off the table under CPB 0375. |
| 6 | Separate commercial and Medicare Advantage workflows. CPB 0375 governs commercial plans only. Medicare Advantage PDT criteria follow Medicare Part B rules. If your billing team applies commercial criteria to MA claims — or vice versa — you'll see denials you can't easily appeal. Build the plan-type filter into your pre-authorization workflow. |
| 7 | Pull a remittance review for PDT claims from the last 90 days. If you've been billing J7309 or CPT 96574 for Aetna commercial members, those claims are likely already denying. Identify any outstanding balances and determine whether a corrected claim or appeal is warranted before the September 26 effective date locks in the updated criteria. |
If your PDT volume is significant and your ICD-10 coding isn't already mapped to the CPB 0375 covered indications list, talk to your compliance officer before the effective date. The indication-dependent dual status of CPT 96570 and 96571 is the kind of ambiguity that generates audit exposure.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Photodynamic Therapy Under CPB 0375
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 96567 | CPT | Photodynamic therapy by external application of light to destroy pre-malignant and/or malignant lesions |
| 96570 | CPT | Photodynamic therapy by endoscopic application of light to ablate abnormal tissue (first 30 minutes) |
| 96571 | CPT | Photodynamic therapy by endoscopic application of light to ablate abnormal tissue (each additional 15 minutes) |
| 96573 | CPT | Photodynamic therapy by external application of light to destroy premalignant lesions of the skin and subcutaneous tissue |
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J7308 | HCPCS | Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg) |
| J7345 | HCPCS | Aminolevulinic acid HCL for topical administration, 10% gel, 10 mg |
| J9600 | HCPCS | Porfimer sodium, 75 mg |
Not Covered / Excluded Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 96570 | CPT | Photodynamic therapy by endoscopic application of light (first 30 min) | Not covered for indications listed in CPB 0375 |
| 96571 | CPT | Photodynamic therapy by endoscopic application of light (each additional 15 min) | Not covered for indications listed in CPB 0375 |
| 96574 | CPT | Debridement of premalignant hyperkeratotic lesion(s) followed with PDT | Not covered for indications listed in CPB 0375 |
| J7309 | HCPCS | Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram | Product discontinued — not covered |
Other CPT Codes Related to CPB 0375
| Code | Type | Description |
|---|---|---|
| 31641 | CPT | Bronchoscopy (rigid or flexible) with destruction of tumor or relief of stenosis by any method other than excision |
| 43228 | CPT | Esophagoscopy, rigid or flexible, with ablation of tumor(s), polyp(s), or other lesion(s), not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique |
| 43229 | CPT | Esophagoscopy, flexible, transoral, with ablation of tumor(s), polyp(s), or other lesion(s) |
| 43270 | CPT | Esophagogastroduodenoscopy, flexible, transoral, with ablation of tumor(s), polyp(s), or other lesion(s) |
| 43272 | CPT | ERCP with ablation of tumor(s), polyp(s), or other lesion(s) |
| 43278 | CPT | ERCP with ablation of tumor(s), polyp(s), or other lesion(s) |
Key ICD-10-CM Diagnosis Codes
This CPB maps to 527 ICD-10-CM codes. Below are the primary covered and contextually relevant diagnosis codes. Verify your specific indication against the full Aetna CPB 0375 code list before billing.
| Code | Description |
|---|---|
| C15.3–C15.9 | Malignant neoplasm of esophagus (obstructing) |
| C16.0–C16.9 | Malignant neoplasm of stomach |
| C18.0–C18.9 | Malignant neoplasm of colon |
| C21.0 | Malignant neoplasm of anus |
| C22.0–C22.9 | Malignant neoplasm of liver and intrahepatic bile ducts (cholangiocarcinoma) |
| C25.0–C25.9 | Malignant neoplasm of pancreas |
| C34.0–C34.10 | Malignant neoplasm of bronchus and lung (microinvasive endobronchial non-small cell; obstructing) |
| C00.0–C14.8 | Malignant neoplasm of lip, oral cavity, and pharynx (squamous cell carcinoma) |
| C30.0–C32.9 | Malignant neoplasm of nasal cavities, middle ear, accessory sinuses, and larynx (squamous cell carcinoma) |
| A63.0 | Anogenital (venereal) warts — appears in CPB, PDT not covered for this indication |
| B00.1 | Herpesviral vesicular dermatitis — appears in CPB, PDT not covered for this indication |
| B07.0 | Plantar wart — appears in CPB, PDT not covered for this indication |
| B07.8 | Other viral warts (verrucous vulgaris) — appears in CPB, PDT not covered for this indication |
| B35.0–B35.6 | Dermatophytosis (superficial mycosis) — appears in CPB, PDT not covered for this indication |
| B36.0 | Pityriasis versicolor — appears in CPB, PDT not covered for this indication |
| B97.7 | Papillomavirus as cause of diseases classified elsewhere — appears in CPB, PDT not covered for this indication |
The non-malignant dermatologic diagnoses (warts, fungal infections, viral skin conditions) are included in the CPB but map to non-covered indications. Don't attach these ICD-10 codes to PDT procedure claims expecting reimbursement. Aetna's position is that PDT for these conditions doesn't meet medical necessity standards under this policy.
Get the Full Picture for CPT 96567
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.